Last reviewed · How we verify
REBLOZYL (LUSPATERCEPT-AAMT)
REBLOZYL (generic name: LUSPATERCEPT-AAMT) is a Erythroid Maturation Agent [EPC] drug developed by CELGENE CORP. It is currently FDA-approved for Myelodysplastic syndrome, beta Thalassemia.
At a glance
| Generic name | LUSPATERCEPT-AAMT |
|---|---|
| Sponsor | CELGENE CORP |
| Drug class | Erythroid Maturation Agent [EPC] |
| Target | Growth/differentiation factor 11, Growth/differentiation factor 8 |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Myelodysplastic syndrome
- beta Thalassemia
Common side effects
- Headache
- Bone Pain
- Arthralgia
- Fatigue
- Cough
- Abdominal Pain
- Diarrhea
- Dizziness
- Nausea
- Influenza
- Viral Upper Respiratory Infection
- Musculoskeletal Pain
Serious adverse events
- Cerebrovascular Accident
- Deep Vein Thrombosis
- Acute Myeloid Leukemia (AML M6)
Key clinical trials
- Phase II Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Patients With Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and (Phase 2)
- A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomita (Phase 3)
- Luspatercept in Patients Affected With Rare Inherited Anemias (Phase 2)
- A Phase II Study of Combination Therapy With Luspatercept in Lower Risk Myelodysplasia: A Tier 1 MyeloMATCH Substudy (Phase 2)
- A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (Phase 1)
- A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis (Phase 2)
- A Phase 4 Study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Ring S (Phase 4)
- A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS) (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- REBLOZYL CI brief — competitive landscape report
- REBLOZYL updates RSS · CI watch RSS
- CELGENE CORP portfolio CI
Frequently asked questions about REBLOZYL
What is REBLOZYL?
REBLOZYL (LUSPATERCEPT-AAMT) is a Erythroid Maturation Agent [EPC] drug developed by CELGENE CORP, indicated for Myelodysplastic syndrome, beta Thalassemia.
What is REBLOZYL used for?
REBLOZYL is indicated for Myelodysplastic syndrome, beta Thalassemia.
Who makes REBLOZYL?
REBLOZYL is developed and marketed by CELGENE CORP (see full CELGENE CORP pipeline at /company/celgene-corp).
What is the generic name of REBLOZYL?
LUSPATERCEPT-AAMT is the generic (nonproprietary) name of REBLOZYL.
What drug class is REBLOZYL in?
REBLOZYL belongs to the Erythroid Maturation Agent [EPC] class. See all Erythroid Maturation Agent [EPC] drugs at /class/erythroid-maturation-agent-epc.
What development phase is REBLOZYL in?
REBLOZYL is FDA-approved (marketed).
What are the side effects of REBLOZYL?
Common side effects of REBLOZYL include Headache, Bone Pain, Arthralgia, Fatigue, Cough, Abdominal Pain. Serious adverse events: Cerebrovascular Accident, Deep Vein Thrombosis, Acute Myeloid Leukemia (AML M6).
What does REBLOZYL target?
REBLOZYL targets Growth/differentiation factor 11, Growth/differentiation factor 8 and is a Erythroid Maturation Agent [EPC].
Related
- Drug class: All Erythroid Maturation Agent [EPC] drugs
- Target: All drugs targeting Growth/differentiation factor 11, Growth/differentiation factor 8
- Manufacturer: CELGENE CORP — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Myelodysplastic syndrome
- Indication: Drugs for beta Thalassemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing